A347740 Stock Overview
Engages in the evaluation and research of dermatological products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
P&K Skin Research Center Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,635.00 |
| 52 Week High | ₩3,530.00 |
| 52 Week Low | ₩2,155.00 |
| Beta | 0.64 |
| 11 Month Change | 6.25% |
| 3 Month Change | -19.05% |
| 1 Year Change | -0.19% |
| 33 Year Change | -51.09% |
| 5 Year Change | n/a |
| Change since IPO | -60.67% |
Recent News & Updates
Shareholder Returns
| A347740 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 1.9% | 7.4% | 0.9% |
| 1Y | -0.2% | 51.8% | 0.8% |
Return vs Industry: A347740 underperformed the KR Life Sciences industry which returned 51.8% over the past year.
Return vs Market: A347740 underperformed the KR Market which returned 0.8% over the past year.
Price Volatility
| A347740 volatility | |
|---|---|
| A347740 Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A347740's share price has been volatile over the past 3 months.
Volatility Over Time: A347740's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 85 | Hae-gwang Lee | www.pnkskin.com |
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs.
P&K Skin Research Center Co., Ltd. Fundamentals Summary
| A347740 fundamental statistics | |
|---|---|
| Market cap | ₩76.68b |
| Earnings (TTM) | ₩5.36b |
| Revenue (TTM) | ₩16.28b |
14.3x
P/E Ratio4.7x
P/S RatioIs A347740 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A347740 income statement (TTM) | |
|---|---|
| Revenue | ₩16.28b |
| Cost of Revenue | ₩8.31b |
| Gross Profit | ₩7.98b |
| Other Expenses | ₩2.62b |
| Earnings | ₩5.36b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 184.04 |
| Gross Margin | 48.98% |
| Net Profit Margin | 32.89% |
| Debt/Equity Ratio | 0% |
How did A347740 perform over the long term?
See historical performance and comparison